CT and clinical assessment in asymptomatic and pre-symptomatic patients with early SARS-CoV-2 in outbreak settings.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
May 2021
Historique:
received: 06 08 2020
accepted: 09 10 2020
revised: 03 09 2020
pubmed: 5 11 2020
medline: 16 4 2021
entrez: 4 11 2020
Statut: ppublish

Résumé

The early infection dynamics of patients with SARS-CoV-2 are not well understood. We aimed to investigate and characterize associations between clinical, laboratory, and imaging features of asymptomatic and pre-symptomatic patients with SARS-CoV-2. Seventy-four patients with RT-PCR-proven SARS-CoV-2 infection were asymptomatic at presentation. All were retrospectively identified from 825 patients with chest CT scans and positive RT-PCR following exposure or travel risks in outbreak settings in Japan and China. CTs were obtained for every patient within a day of admission and were reviewed for infiltrate subtypes and percent with assistance from a deep learning tool. Correlations of clinical, laboratory, and imaging features were analyzed and comparisons were performed using univariate and multivariate logistic regression. Forty-eight of 74 (65%) initially asymptomatic patients had CT infiltrates that pre-dated symptom onset by 3.8 days. The most common CT infiltrates were ground glass opacities (45/48; 94%) and consolidation (22/48; 46%). Patient body temperature (p < 0.01), CRP (p < 0.01), and KL-6 (p = 0.02) were associated with the presence of CT infiltrates. Infiltrate volume (p = 0.01), percent lung involvement (p = 0.01), and consolidation (p = 0.043) were associated with subsequent development of symptoms. COVID-19 CT infiltrates pre-dated symptoms in two-thirds of patients. Body temperature elevation and laboratory evaluations may identify asymptomatic patients with SARS-CoV-2 CT infiltrates at presentation, and the characteristics of CT infiltrates could help identify asymptomatic SARS-CoV-2 patients who subsequently develop symptoms. The role of chest CT in COVID-19 may be illuminated by a better understanding of CT infiltrates in patients with early disease or SARS-CoV-2 exposure. • Forty-eight of 74 (65%) pre-selected asymptomatic patients with SARS-CoV-2 had abnormal chest CT findings. • CT infiltrates pre-dated symptom onset by 3.8 days (range 1-5). • KL-6, CRP, and elevated body temperature identified patients with CT infiltrates. Higher infiltrate volume, percent lung involvement, and pulmonary consolidation identified patients who developed symptoms.

Identifiants

pubmed: 33146796
doi: 10.1007/s00330-020-07401-8
pii: 10.1007/s00330-020-07401-8
pmc: PMC7610169
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3165-3176

Subventions

Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NIH HHS
ID : CL040015
Pays : United States
Organisme : NIH HHS
ID : BC011242
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : ITAC

Commentaires et corrections

Type : ErratumIn

Références

Clin Radiol. 2020 May;75(5):329-334
pubmed: 32265036
Int J Infect Dis. 2020 Jun;95:174-175
pubmed: 32251796
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Lancet Infect Dis. 2020 Jun;20(6):655-656
pubmed: 32171389
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Science. 2021 Jan 15;371(6526):
pubmed: 33234698
Lancet Infect Dis. 2020 Sep;20(9):1043-1050
pubmed: 32539988
N Engl J Med. 2020 May 28;382(22):2158-2160
pubmed: 32329972
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
Radiol Cardiothorac Imaging. 2020 Apr 21;2(2):e200196
pubmed: 33778576
Sci China Life Sci. 2020 May;63(5):706-711
pubmed: 32146694
Clin Microbiol Infect. 2020 Jul;26(7):957-959
pubmed: 32234453
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
J Infect. 2020 Aug;81(2):e55-e58
pubmed: 32335168
N Engl J Med. 2020 May 28;382(22):2163-2164
pubmed: 32283004
Am J Respir Crit Care Med. 2020 May 1;201(9):1150-1152
pubmed: 32200654
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Chin J Acad Radiol. 2020;3(1):1-3
pubmed: 32292879
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Balkan Med J. 2020 Apr 13;37(4):229-230
pubmed: 32279479
Int J Infect Dis. 2020 May;94:133-138
pubmed: 32247826
J Med Virol. 2020 Oct;92(10):1795-1796
pubmed: 32311142
Radiol Cardiothorac Imaging. 2020 Apr 6;2(2):e200092
pubmed: 33778564
Radiol Cardiothorac Imaging. 2020 Apr 07;2(2):e204002
pubmed: 33779623
J Med Virol. 2020 Oct;92(10):1938-1947
pubmed: 32311109
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
J Infect Dis. 2010 May 15;201(10):1509-16
pubmed: 20377412
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
J Am Coll Radiol. 2020 Jun;17(6):710-716
pubmed: 32208140
Lancet Infect Dis. 2020 Apr;20(4):410-411
pubmed: 32087116

Auteurs

Nicole Varble (N)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
Philips Research North America, Cambridge, MA, USA.

Maxime Blain (M)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.

Michael Kassin (M)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, USA.

Sheng Xu (S)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.

Evrim B Turkbey (EB)

Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, USA.

Amel Amalou (A)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.

Dilara Long (D)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.

Stephanie Harmon (S)

National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA.

Thomas Sanford (T)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
State University of New York Upstate Medical University, Syracuse, NY, USA.

Dong Yang (D)

Nvidia Corporation, Bethesda, MD, USA.

Ziyue Xu (Z)

Nvidia Corporation, Bethesda, MD, USA.

Daguang Xu (D)

Nvidia Corporation, Bethesda, MD, USA.

Mona Flores (M)

Nvidia Corporation, Bethesda, MD, USA.

Peng An (P)

Department of Radiology, Xiangyang NO. 1 People's Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China.

Gianpaolo Carrafiello (G)

Department of Radiology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Health Sciences, University of Milano, Milan, Italy.

Hirofumi Obinata (H)

Self-Defense Forces Central Hospital, Tokyo, Japan.

Hitoshi Mori (H)

Self-Defense Forces Central Hospital, Tokyo, Japan.

Kaku Tamura (K)

Self-Defense Forces Central Hospital, Tokyo, Japan.

Ashkan A Malayeri (AA)

Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, USA.

Steven M Holland (SM)

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Tara Palmore (T)

Hospital Epidemiology Service, NIH Clinical Center, Bethesda, MD, USA.

Kaiyuan Sun (K)

Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD, USA.

Baris Turkbey (B)

Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, USA.
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Bradford J Wood (BJ)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA. bwood@nih.gov.
Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, USA. bwood@nih.gov.
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. bwood@nih.gov.
National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD, USA. bwood@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH